Clinical Trials on Wounds and Injuries

Total 415585 results

Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
Biogen

Terminated

Natalizumab (Tysabri) Re-Initiation of Dosing (STRATA)

Relapsing-Remitting Multiple Sclerosis

Finland, Germany, Spain, Belgium, Italy, Canada, France, New Zealand, Israel, Hungary, Greece, Australia, Netherlands, United Kingdom, Denmark, Ireland, Sweden, Poland, Czech Republic, Switzerland, Turkey
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3

Hepatitis C, Chronic

Austria
Biogen
AbbVie

Completed

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis (SELECT)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Green Cross Corporation

Completed

A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients

Hepatitis B Infection

Korea, Republic of
Genzyme, a Sanofi Company

Completed

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA (EMERALD)

Relapsing-remitting Multiple Sclerosis

Belgium, Spain, France, Netherlands
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

Hepatitis C, Chronic

United States
PD Dr. Marcus Müller
BfARM, Bonn; DZNE, Bonn

Unknown

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RESI)

Relapsing-remitting Multiple Sclerosis

Germany
Clare Twist
National Institutes of Health (NIH)

Terminated

Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia

Leukemia | Leukemia, Lymphocytic, Acute | Acute Lymphoid Leukemia (ALL)

United States
Bristol-Myers Squibb

Completed

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Hepatitis C Virus Infection

Australia, France, Germany, Korea, Republic of, Sweden, Taiwan, United Kingdom, United States, Canada, Mexico, Austria, Italy, Spain, Denmark, Argentina, Poland, Ireland, Greece, New Zealand
The Lymphoma Academic Research Organisation
Pfizer

Completed

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Diffuse Large B-Cell Lymphoma

France, Belgium
University of Cologne

Completed

Molecular Imaging With Erlotinib and Bevacizumab (MIMEB)

Non-Small-Cell Lung Carcinoma

Germany
University Hospital Muenster

Unknown

DTI in Children With Multiple Sclerosis

Clinically Isolated Syndrome, CNS Demyelinating | Multiple Sclerosis - Relapsing Remitting

Germany
M.D. Anderson Cancer Center

Completed

Late Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States
Nantes University Hospital

Completed

Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

France
University Hospital Southampton NHS Foundation...
Janssen-Cilag Ltd.

Completed

A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib (REMoDL-B)

Lymphoma, Large B-Cell, Diffuse

United Kingdom, Switzerland
Dong-A University Hospital

Completed

Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)

Lymphoma

Korea, Republic of
Biogen

Terminated

Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) (IMPROVE)

Multiple Sclerosis, Relapsing-Remitting | Relapsing-Remitting Multiple Sclerosis

Canada
Hoffmann-La Roche

Completed

An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

Hepatitis C, Chronic

Hungary
Hoffmann-La Roche

Completed

A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients

Hepatitis C, Chronic

Slovenia
Japan Blood Products Organization

Completed

Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome

Guillain-Barré Syndrome

Japan
AIDS Malignancy Consortium
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma

Lymphoma

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Hepatitis C, Genotype 1

United States, Australia, France, Germany, Spain, Canada, Puerto Rico, Argentina, Brazil, Russian Federation, United Kingdom, Italy, Belgium
Hoffmann-La Roche

Completed

REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy

Hepatitis C, Chronic

Belgium, France, Germany, Italy, Spain, Sweden, United States, Greece, Portugal, Turkey, Switzerland, Canada, United Kingdom, Brazil
Biogen

Completed

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

Japan
Sheba Medical Center

Completed

Mozobil for Autologous Stem Cell Mobilization

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Autologous Stem Cell Transplantation | Stem Cell Mobilization

Israel
University of Missouri, Kansas City

Completed

Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS (MIMS)

Relapsing-remitting Multiple Sclerosis

United States
University of Missouri, Kansas City
National Multiple Sclerosis Society

Completed

Development of a Motivational Intervention to Improve Treatment Adherence in MS (MIMS)

Relapsing-remitting Multiple Sclerosis

United States
Merck Sharp & Dohme LLC

Completed

Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181) (FAST-4)

Hepatitis C, Chronic
Presidio Pharmaceuticals, Inc.

Completed

A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients

Hepatitis C, Chronic

United Kingdom, Mauritius
Wenqi Jiang

Unknown

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

China
UCB Pharma

Terminated

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Rheumatoid Arthritis | Crohn's Disease

Russian Federation
Merck Sharp & Dohme LLC

Completed

Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) (PRACTICE)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)

Hepatitis C | Hepatitis C, Chronic
University Hospital, Strasbourg, France

Unknown

Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C

Hepatitis C

France
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment

Non-small Cell Lung Cancer

China
Biogen

Withdrawn

Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate (TECNERGY)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) (REFINE)

Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Germany, Belgium
Janssen R&D Ireland

Completed

An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients

Hepatitis C, Chronic

China, Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)

Hepatitis C | Hepatitis C, Chronic
Hoffmann-La Roche

Completed

A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)

Hepatitis C, Chronic

Czech Republic
Merck Sharp & Dohme LLC

Terminated

Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)

Hepatitis C | Hepatitis C, Chronic
Sinocelltech Ltd.

Unknown

A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma

B-cell Non Hodgkin's Lymphoma

China
Gilead Sciences

Completed

Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Hepatitis C Virus

Egypt
University of Michigan Rogel Cancer Center
Novartis

Withdrawn

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

Chronic Myeloid Leukemia

United States
Université de Sherbrooke

Completed

Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa

Hepatitis C, Chronic | HIV | HTLV-1
Merck Sharp & Dohme LLC

Completed

Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)

Hepatitis C | Hepatitis C, Chronic
Bayer

Withdrawn

Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)

Multiple Sclerosis

Sweden, Denmark

3

Subscribe